NCT06541639View on ClinicalTrials.gov

EVM16 Injection As a Single and Combination with Tislelizumab in Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

March 4, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

June 30, 2028

Conditions
Advanced or Recurrent Solid Tumors
Interventions
BIOLOGICAL

EVM16

cancer vaccine

DRUG

Tislelizumab

Anti-PD1 antibody

Trial Locations (2)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

200135

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
collaborator

Shanghai Cancer Centre

OTHER

collaborator

Everest Medicines (China) Co.,Ltd.

INDUSTRY

lead

Peking University

OTHER